REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
08/06/2025
Voltar para busca
Dado oficial do USPTO
MOLECULARHEALTH
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
MOLECULARHEALTH
ST13
US500000085583366Classe
42, 44
Pedido
85583366
Registro
4975047
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
72
Atualização mais recente
09/06/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
42, 44
Data de depósito
29/03/2012
Data de registro
07/06/2016
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
07/06/2023
Última transação
09/06/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
701
Cadastro oficial
Supplemental Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
16
Localização do titular
HEIDELBERG, DE
Examinador
DAHLING,KRISTIN M
Unidade examinadora
L50
Localização atual
TMEG LAW OFFICE 105
Titulares e representantes
Titulares
MOLECULAR HEALTH GMBH
Molecular Health AG
Representantes
Robert S. Weisbein Foley & Lardner LLP
Classificação técnica
Classes Nice
Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 42
Data collection for medical and scientific research purposesthe collection and systematic sorting of clinical and patient data comprising patient-specific molecular and genomic datapatient specific clinical data and scientific clinical studies; data collection for medical and scientific research purposesthe collection of mathematic and statistical dataclinical datapatient data and data of clinical studies relating to clinical response to drug treatments; providing medical and scientific research information and scientific consulting in the fields of pharmaceutical side effectsgenomicsbiological medicine and translational medicine; providing an online database comprised of medicalpharmaceuticalbiological and genomic information for scientific research purposes; providing an online searchable database in the fields of biological medicaltranslational medicineinterventional epidemiologybioinformaticsclinical information technologygenomic data and genomic sequence analysis for scientific research purposes; design and development of computer software in the fields of biologymedicinebioinformatics; design and development of computer software for integration of patient specific datamolecular test resultsclinical studies and scientific results; providing online non-downloadable computer software for use by healthcare professionals for medical treatment research; design and development of databases featuring biomarker data; providing an online searchable database for clinical and scientific research in the field of medicaldiagnostic and treatment research; Software as a Service (SAAS) services featuring software for providing information for patient treatment by enabling the retrieval and correlation of genomic datadrug protocolsclinical profiling and integration and statistical analysis of data for medical purposes; providing online non-downloadable software for retrieval and correlation of genomic datadrug protocolsclinical profiling and integration and statistical analysis of data for medical diagnostic and treatment research purposes; medical research and scientific research and scientific consulting servicesdesigning and conducting drug safety and dosage assessment and drug compatibility studies in the field of cancer therapy for others; consulting services in the field of pharmaceuticals and geneticsconducting drug safety and dosage assessment and in drug compatibility studies in the field of cancer treatment therapy for others relating to diagnosticprophylactic and therapeutic properties of pharmaceuticals; Providing online non-downloadable computer software for use by healthcare professionals for medical diagnostics
Classe 44
Providing an online database featuring medical information and diagnosticprophylactic and therapeutic properties of pharmaceuticalsgenomic information as it relates to medical diagnosis and treatment; pharmaceutical consulting services in pharmaceuticals and genetics in relation to patient medical treatment options; medical consulting services with respect to the treatment and diagnosis of individuals in the fields of clinical pharmacology and the analysis of dose effect relationships for treatment purposes; providing pharmaceutical informationinformation about drug safety and drug compatibility in relation to cancer therapy and the treatment of individual patients; medical consulting services in the fields of patient treatment and treatment protocols
Publicações
Histórico de despachos e eventos da marca no USPTO.
72 publicações encontradas
NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
07/06/2023
8.OK
REGISTERED - SEC. 8 (6-YR) ACCEPTED
07/06/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
05/06/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
17/12/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
17/12/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
17/12/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
17/12/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
17/12/2022
ES8R
TEAS SECTION 8 RECEIVED
06/12/2022
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
07/06/2021
R.SR
REGISTERED-SUPPLEMENTAL REGISTER
07/06/2016
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
05/05/2016
CNTA
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
28/04/2016
XAEC
EXAMINER'S AMENDMENT ENTERED
27/04/2016
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
27/04/2016
GNEA
EXAMINERS AMENDMENT E-MAILED
27/04/2016
CNEA
EXAMINERS AMENDMENT -WRITTEN
27/04/2016
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
26/04/2016
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
29/03/2016
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
11/03/2016
CNTA
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
08/03/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/03/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/03/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/03/2016
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
21/12/2015
GNRT
NON-FINAL ACTION E-MAILED
21/12/2015
CNRT
NON-FINAL ACTION WRITTEN
21/12/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/12/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/12/2015
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
30/11/2015
DOCK
ASSIGNED TO EXAMINER
19/10/2015
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
31/05/2015
GNRT
NON-FINAL ACTION E-MAILED
31/05/2015
CNRT
NON-FINAL ACTION WRITTEN
31/05/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/05/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/05/2015
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
28/04/2015
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
29/10/2014
GNSI
INQUIRY TO SUSPENSION E-MAILED
29/10/2014
CNSI
SUSPENSION INQUIRY WRITTEN
29/10/2014
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
07/10/2014
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
20/08/2014
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
07/04/2014
GNSL
LETTER OF SUSPENSION E-MAILED
07/04/2014
CNSL
SUSPENSION LETTER WRITTEN
07/04/2014
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
20/03/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
20/03/2014
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
14/03/2014
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
04/10/2013
GNSI
INQUIRY TO SUSPENSION E-MAILED
04/10/2013
CNSI
SUSPENSION INQUIRY WRITTEN
04/10/2013
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
19/09/2013
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
18/03/2013
GNSL
LETTER OF SUSPENSION E-MAILED
18/03/2013
CNSL
SUSPENSION LETTER WRITTEN
18/03/2013
XAEC
EXAMINER'S AMENDMENT ENTERED
07/03/2013
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
07/03/2013
GNEA
EXAMINERS AMENDMENT E-MAILED
07/03/2013
CNEA
EXAMINERS AMENDMENT -WRITTEN
07/03/2013
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
31/01/2013
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
31/01/2013
ALIE
ASSIGNED TO LIE
24/01/2013
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
22/01/2013
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
22/01/2013
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
22/07/2012
GNRT
NON-FINAL ACTION E-MAILED
22/07/2012
CNRT
NON-FINAL ACTION WRITTEN
22/07/2012
DOCK
ASSIGNED TO EXAMINER
10/07/2012
MPMK
NOTICE OF PSEUDO MARK MAILED
05/04/2012
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/04/2012
NWAP
NEW APPLICATION ENTERED
02/04/2012
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace MOLECULARHEALTH ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.